<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008900</url>
  </required_header>
  <id_info>
    <org_study_id>21-5040</org_study_id>
    <nct_id>NCT05008900</nct_id>
  </id_info>
  <brief_title>Timing of Post-prostatectomy PSMA Imaging</brief_title>
  <acronym>TOPP</acronym>
  <official_title>A Phase II Randomized Feasibility Study Comparing Early Salvage Radiotherapy Versus Surveillance With Delayed Repeat PSMA PET/CT Imaging in Patients Presenting With Early Biochemical Relapse of Prostate Cancer Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will randomize patients presenting with early BCR with a negative baseline&#xD;
      PSMA PET/CT, to upfront SRT or surveillance. Early BCR is defined as a PSA relapse of &gt;0.1 to&#xD;
      &lt;0.3 ng/mL. Patients in the surveillance arm will be monitored with PSA every 3 months. A&#xD;
      repeat PSMA PET/CT will be undertaken when the PSA reaches a target level of &gt;0.5 to &lt;1.0&#xD;
      ng/mL. Both early radiation treatment and surveillance with repeat PSMA PET/CT imaging are&#xD;
      within patterns of practice locally; therefore, the investigators believe that there is&#xD;
      clinical equipoise on this subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2031</completion_date>
  <primary_completion_date type="Anticipated">September 2030</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Feasibility</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surveillance with delayed PSMA PET scan</measure>
    <time_frame>7 years</time_frame>
    <description>This study will assess the feasibility of surveillance with delayed repeat PSMA PET/CT in patients with BCR of prostate cancer following radical prostatectomy with negative baseline PSMA PET/CT. A treating physician questionnaire will be completed prior to screening and enrollment, as well as PSA results every three months for surveillance patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will go on surveillance. Routine PSA will be conducted and a repeat PSMA PET/CT imaging will be conducted when the PSA rises to greater than 0.5 to less than 1.0 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage radiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA of greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will receive salvage radiotherapy to the prostate bed. This radiotherapy may or may not include the pelvic lymph nodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Salvage radiotherapy</intervention_name>
    <description>Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.</description>
    <arm_group_label>Surveillance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven prostate cancer&#xD;
&#xD;
          -  pT1-T4 pN0/Nx cM0&#xD;
&#xD;
          -  PSA at BCR &gt;0.1 - &lt;0.3 ng/mL post-radical prostatectomy&#xD;
&#xD;
          -  PSMA PET/CT negative at BCR post radical prostatectomy&#xD;
&#xD;
          -  Planned SRT to prostate bed +/- pelvic lymph nodes&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Informed consent: All patients must sign a document of informed consent indicating&#xD;
             their understanding of the investigational nature and risks of the study before any&#xD;
             protocol related studies are performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or post prostatectomy androgen deprivation use&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Other contraindications to radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Srinivas Raman, MD</last_name>
    <phone>416-946-2320</phone>
    <email>srinivas.raman@rmp.uhn.ca</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

